Zoetis Inc. Q3 FY2026 earnings call

• Industry Dynamics: Pet care faces headwinds from rising veterinary costs and affordability pressures, leading to a shift toward cats (less medicalized) and value-conscious spending. Livestock benefits from global protein demand and food security trends.
• Strategic Priorities: Focus on leveraging portfolio diversity (especially in Dermatology), expanding access via evidence-based marketing (Medical Hub), and advancing innovation lifecycle products.
• Commercial Execution: Promotional investments slowed share loss in Dermatology (from -7% in Q2 to -4% in Q3) and maintained leadership in Parasiticides (Simparica Trio at 22.5% share).
• Innovation Pipeline: Met 2026 major market approval milestones early (e.g., Convenia RTU). Expecting approval of long-acting Cytopoint in Q4 2026 and Simparica Duo by year-end. Breakthrough categories include CKD, oncology, and obesity.
• Cost Discipline: Adjusted operating expenses flat operationally; SG&A declined 1% for the full year. Gross margin impacted by pricing initiatives and product mix but supported by cost savings.
• New Leadership: CFO Jay Saccaro emphasizes understanding operations, ensuring competitive cost structure, and evaluating financial metrics for future guidance.

• Companion Animal: Revenue of $1.6 billion, down 5% globally (down 13% in the US, up slightly internationally). Driven by declines in dermatology (Apoquel, Cytopoint) due to generic competition and softer clinic visits, partially offset by growth in parasiticides (Simparica) and OA pain management.
• Livestock: Revenue of $797 million, up 7%. Strong performance driven by cattle, swine, and poultry demand, with international growth outpacing US growth.
• Companion Animal Diagnostics: Revenue of $122 million, up 13%, driven by acquisitions (VitalRaz, VPG) and underlying adoption of point-of-care platforms.

• Full Year 2026 Revenue: Narrowed to $9.22–$9.32 billion, representing an organic operational decline of -2% to -1%.
• Full Year 2026 Adjusted Net Income: Raised to $2.60–$2.64 billion, representing an organic operational decline of -7% to -5%.
• Full Year 2026 Adjusted Diluted EPS: Raised to $6.25–$6.35.
• 2027 Outlook: No specific numerical guidance provided. Management will plan prudently, assuming no improvement in macro environment or pet owner spending, and that competitive dynamics remain persistent. Limited revenue contribution expected from new launches in 2027, with impact building into 2028.

• Macroeconomic Pressures: Rising veterinary service costs and consumer affordability concerns are reducing clinic visits and altering pet ownership demographics (shift to cats).
• Competitive Intensity: Intense generic competition in Dermatology (Convenia, Serenia) and new entrants in injectable dermatology and parasiticides are pressuring share and necessitating aggressive gross-to-net promotional spending.
• Regulatory and Supply Chain: Dependence on FDA approvals for pipeline products; potential supply challenges for new launches.
• Cyclical Nature of Livestock: Results influenced by disease outbreaks, weather, and local production cycles.
• Margin Pressure: Strategic pricing initiatives and promotional investments may continue to impact gross margins until share stabilization occurs.

Q: Analyst asked about the impact of promotional activities on business traction and considerations for 2027 guidance vs. street expectations. / A: CEO noted promotions slowed DERM share loss (-7% to -4%) and held Parasiticide share (22.5%). CFO stated they are being conservative for 2027, not assuming macro changes or reduced competition, and noting R&D impact is more prominent in 2028/29. He declined to comment on street models.

Q: Analyst asked if Simparica Trio growth will normalize like Nexgard did, and regarding Cytopoint's defense against competitors like Befrenna. / A: CEO highlighted Trio's strong international runway and upcoming Simparica Duo approval. Regarding Cytopoint, she noted it fared well due to efficacy and competitor supply issues. Long-acting Cytopoint is on track for Q4 approval and H1 2027 launch to expand the category.

Q: Analyst asked about implied Q4 deceleration and sustainability of livestock growth off a high base. / A: CFO explained Q4/Q3 seasonality and promotional timing cause a high-single-digit drop between quarters, but full-year trajectory remains -1% to -2%. CEO affirmed livestock strength due to protein demand, citing broad species growth and confidence in vaccines/preventatives positioning.

Q: Analyst asked if gross-to-net promos are temporary or permanent for margins, and feedback on Lanivia/Pertella. / A: CEO expects share stabilization in 12-18 months, after which focus shifts to growth, implying promos may taper. CFO noted full-year margins shaping up in line/better than expected due to SG&A savings. CEO reported high vet/pet owner satisfaction (>95%) for Lanivia/Pertella, driving international OA pain growth despite some cannibalization.

Q: Analyst asked about DERM volume/price split and retail channel trends. / A: CEO noted retail growth slowing overall but home delivery stronger; investments in MAP pricing helped defend retail. CFO clarified DERM decline was primarily volume-driven, with price impact higher than corporate average due to gross-to-net investments rather than list price cuts.